Hewamana Saman, Kandabadage Lakmali, Skandarajah Thurairajah, Pieris Natasha, Perera Eranga, Harischandra Mahesh, Wijewickrama Ananda, Wickramarathna Chandana, Somasundaram Gnani, Srinivasan Vadivelu, Somiah Surjit, Jayawardena Priyankara, Perera Mehendra, Gunasekera Dehan, Jayasinghe Chathuri, Constantine Godvin, Munasinghe Sanjeewa, De Silva Chandu, Wijesiriwardena Bandula, Balawardena Jayantha
Clinical Haematology Unit Lanka Hospitals Colombo Sri Lanka.
National Cancer Institute Colombo Sri Lanka.
EJHaem. 2021 May 13;2(3):555-561. doi: 10.1002/jha2.191. eCollection 2021 Aug.
There are no published data on long-term survival and applicability of treatment protocols from developed countries in acute myeloid leukaemia (AML) in Sri Lanka. Eighty-seven AML patients were reviewed; there were 56 newly diagnosed patients between 18 and 65 years. Thirty-one out of 33 who started treatment achieved complete remission after first cycle of treatment. The induction mortality was one of 33. Twelve out of 20 patients who completed treatment are alive at the time of analysis. The estimated 5-year overall survival rate is 0.629. Strict infection control and treatment and superior clinical experience may have contributed towards better outcome.
关于发达国家急性髓系白血病（AML）治疗方案在斯里兰卡的长期生存率和适用性，目前尚无公开数据。对87例AML患者进行了回顾性研究；其中有56例新诊断患者，年龄在18至65岁之间。开始治疗的33例患者中，有31例在第一个治疗周期后实现完全缓解。诱导死亡率为33例中的1例。在分析时，完成治疗的20例患者中有12例存活。估计5年总生存率为0.629。严格的感染控制与治疗以及卓越的临床经验可能促成了更好的治疗结果。
